Ranbaxy has entered a strong earnings trajectory with high visibility on FTF upsides till CY14 and improving outlook for base business. Ranbaxy’s focus on settling Para IV cases and more effective operational execution supported by business development moves has started to deliver. Steady growth in emerging markets (2/3rd of sales) and recovery in US generics will drive 18% CAGR in USD revenues and 320bp expansion in EBITDA margin over CY07-09 in base business. Ranbaxy is expected to generate ~USD2.5bn gross profit from the confirmed FTF opportunities over CY08-14. Given the strong earnings outlook and significant incremental positive news flow potential, we expect Ranbaxy to get rerated. Reiterate Outperformer with SOTP-based price target of Rs610 excluding NCE R&D business value. Ranbaxy is one of our top picks in the pharma space. FTF value unlocking begins: Ranbaxy has among the best Para IV pipelines in the business with 18 potential FTF Para IVs. Based on visibility on eight of these FTFs, Ranbaxy will have 6-month exclusivity on at least one >$1bn sales molecule each year (barring 2013) from CY08-14 along with Nexium settlement revenues that will accrue over CY09-14. Ranbaxy is expected to generate ~$2.5bn of gross profit from this opportunity which, in turn, can create multiple new growth engines for the company. Base business; gradual but steady progress: Driven by recovery in US generics market (20% growth in CY07, 17% CAGR over CY07-10E) and strong growth momentum in non-US/ EU markets (21% CAGR in CY07-10E). Ranbaxy’s early entry in newer markets of Canada, Japan, Nigeria, Mexico, etc is beginning to pay off. Multiple sales growth initiatives undertaken recently will accelerate the momentum. Golden phase; stock to get rerated: We believe the market will begin to view FTF upsides as an integral component of Ranbaxy’s business model and reward the strong multi-year earnings growth visibility. Exclusivity earnings flow will also enable Ranbaxy to further strengthen its base business. Demerger of the NCE R&D business will also trigger value unlocking. Ranbaxy is one of our top picks in the space.
Live Online Trading News, Live Online Stock Prices NSE, BSE, Live Online Stock Recommendations
www.mReach.net ... for Live TV, Radio & FM channelswww.mReach.netFor Live TV, Radio & FM channels |
Live BSE Live NSE |
Tuesday, June 10, 2008
Stock Recommendations:: Ranbaxy
Stock Recommendations:: Larsen & Toubro, Mahindra & Mahindra (L&T, M&M)
Larsen & Toubro Performance beats expectations Result highlights Mahindra & Mahindra Price target revised to Rs800 Result highlights
Recommendation: Buy
Price target: Rs4,044
Current market price: Rs2,882
Recommendation: Buy
Price target: Rs800
Current market price: Rs606
Stock Recommendations:: Mold-Tek, Tata Motors
Mold-Tek Technologies Price target revised to Rs169 Result highlights Tata Motors Price target revised to Rs680 Result highlights
Recommendation: Buy
Price target: Rs169
Current market price: Rs71
Recommendation: Hold
Price target: Rs680
Current market price: Rs532
Stock Recommendations:: Opto Circuits India, Deepak Fertilisers & Petrochemicals Corporation
Opto Circuits India Results in line with estimates Result highlights Deepak Fertilisers & Petrochemicals Corporation Benefits delayed Result highlights
Recommendation: Buy
Price target: Rs460
Current market price: Rs316
Recommendation: Buy
Price target: Rs169
Current market price: Rs100
Tuesday, May 13, 2008
Day Trading Strategies, Intraday Trading Strategies Rules
Day Trading / Intraday Trading, Rules Strategies
1. Don't Fight The Trend
Go long a stock only when it is strong (up) on the day. Same for shorts (only short down stocks).
2. Don't Overtrade
Enter a maximum of three trades on any given day. Be selective.
3. Consistent Trade Sizes
Each trade should only consist of buying between 100 to 300 shares. Never more.
4. Buy Near Support Levels
Never chase a stock way above its support levels. Wait for a pullback.
5. Manage Losses
Never take a loss of over 10% on any trade. Enter only trades where the stop, if triggered, will result in a loss of less than $10%
6. The 30 Minute Rule
Never enter a trade in the first 30 minutes of trading.
7. Overnight Rule
Any overnight holding can only consist of 100 shares. Only one holding. Again, be selective.
Trading is all about profits and losses.... But, successful trading is about making your losses small and profits big.....
Tuesday, April 22, 2008
Stock Recommendations: Wipro, TCS, Satyam, Axis Bank
Trade Recommendation:: Wipro Price target revised to Rs525 Result highlights Trade Recommendation:: Axis Bank Results above expectations Result highlights Trade Recommendation:: Satyam Computer Services Healthy guidance for FY2009 Result highlights Trade Recommendation: Tata Consultancy Services Q4FY2008 results: First-cut analysis Result highlights
Price target: Rs525
Current market trading price: Rs453
Price target: Rs1,150
Current market price: Rs881
Trade Recommendation: Price target: Rs505
Current market trading price: Rs459
Price target: Under review
Current market price: Rs992
Friday, April 18, 2008
Trade Recommendation: Ranbaxy Laboratories, Infosys, Zee News, HCL
Trade Recommendation:: Ranbaxy Laboratories Ranbaxy settles on Nexium; price target revised to Rs625 Key points Trade Recommendation:: Infosys Technologies Result highlights Trade Recommendation:: Zee News Q4FY2008 results: First-cut analysis Result highlights Trade Recommendation:: HCL Technologies Q3FY2008 results: First-cut analysis Result highlights
Trade Recommendation: Buy
Price target: Rs625
Current market trading price: Rs482
Trade Recommendation: Buy
Price target: Rs1,940
Current market trading price: Rs1,510
Recommendation: Buy
Price target: Rs79
Current market price: Rs57
Trade Recommendation: Buy
Price target: Under review
Current market trading price: Rs246
Tuesday, April 15, 2008
Stock Recommendation:: Reliance Industries
RIL stock price has corrected by over 22% from its peak resulting in drop in expectation value. With atleast 9 discoveries under appraisal (two more discoveries over the last three weeks), highly competitive off-gas based petrochem complex on the anvil, we believe, risk-reward has turned favourable and presents a well diversified growth opportunity. We are upgrading the stock from Neutral to Outperform, with a base case target price of Rs3025/share, an upside of ~19% from current levels. RIL is now our top pick in the oil and gas / Petrochem space. Key arguments: 1. Potential risk to refining margin is overstated. Margins remain robust. We maintain that refining margins are headed down. However, we believe, the risk to refining margins is being overdone. Refining margins remain robust, with March month Singapore complex averaging US$8.5/bbl (our long term Singapore GRM average is USD 6/bbl and USD12.75/bbl for RIL). Though, this is seasonal (peaking in the month of May) and is not sustainable, we believe, a crash to below US$5/bbl on a sustained basis is highly unlikely. While weak global economic growth and its impact on OECD oil demand remains a concern, with a relatively weak demand elasticity and support from developing countries, global demand, is reasonably well placed. A relatively weak supply pipeline and upgradation to higher fuel norms across major consuming countries are set to provide downside support. Squeezed EPC resource base and escalating capex costs are delaying refinery commissioning over the next three years, especially in the Middle-East. While, scheduled capacity commissioning correspond to steady demand growth, we believe, slippages by few months, which are very common, would push it down further, keeping demand-supply fairly balanced, even if demand were to be impacted to global GDP growth. In the case of RIL, gasification of coke and value addition to refinery off-gases (scheduled for FY11-12) along with ability to produce Euro IV & V fuels, are set to support the margins. We believe, RIL’s refining business deserves a valuation premium to global multiples on account this. 2. E&P related positive newsflow to be the key driver of stock performance Appraisal of significant discoveries in Cauvery, KG and Mahanadi basins in India along with Yemen discoveries are likely to provide a steady flow of positive news, driving stock performance. Pronouncements by Niko and Hardy oil, minority stake holders in some of these blocks indicate very large reserve potential in the discoveries, comparable to KG-D6. GCA’s (Gaffney, Cline & Associates) report (Competent Person’s report) to Hardy oil indicate potential reserves running into several TCF in D9, while D3 is supposed to be more favourably sited with respect to existing discoveries in KG basin. Pronouncements by Niko too indicate large potential in D4. Atleast nine discoveries are under appraisal in KG-D6, Cauvery, KG D5 etc are likely to add to SOTP value. Further, a large CBM resource base and a mix of highly prospective acreage in prolific basins provide a good base for future upsides from E&P. With scheduled arrival of new rigs for deepsea drilling over the next 12-18 months, new discoveries are likely We have valued the reserves based on P/CF multiple, across three scenarios, base-bull-bear cases. 3. a. Petrochem – polyester could surprise Petrochem downcycle from 1QCY09 is already in the price as it is the consensus view. No major suprises are likely, as we have already built in decline in margin in all through FY09. We believe, polyester margin recovery would cushion the impact of ethylene-propylene cycle downtrend over the next couple of years and could surprise the market. Buoyant cotton prices further provides scope for polyester price upside. Polyester delta over PTA and MEG is close to its cash cost and could only improve from here. b. Gas based facilities – superior profitability, deserves valuation premium With IPCL in its fold, RIL is best placed to leverage high petrochem product prices (primarily a function of high crude prices, though higher margins too contributed). Domestic gas prices have not risen much, leading to vastly superior margins for gas based petrochem producers in the country compared to naphtha based producers globally. Gas based cracker margins are about 30-50% higher than naphtha based ones. With crude prices unlikely to fall below US$60/bbl and gas prices unlikely to move up sharply, we believe, Indian gas based crackers would remain more profitable than naphtha based ones for some time to come. Hence, we believe, they have to be valued at a premium. Domestic C2 prices continue to be linked to natural gas prices, though C3 is linked to international propane price. Some debottlenecking is in the pipeline in IPCL’s gas cracker as well as PVC, which is set to add to value. c. Off-gas based petrochem plant – vastly superior economics Off-gas based petrochem plant (scheduled for FY11-12 commissioning) offers vastly superior economics vis-à-vis naphtha as well as domestic gas. The relative feedstock cost advantage is ~0.4x vis-à-vis 0.6x for gas based plant, with 1x being the benchmark based on naphtha based plant. These numbers correspond to a crude price range of about US$70-80/bbl and hence would be even more favourable at current crude prices. We believe this plant too would be also command valuation premium over global averages. 4. Large cashflow – set to fuel growth With very large cashflows ranging between Rs250-300b from FY10 (not adjusted for capex in the pipeline), we believe, growth is likely to be accelerated. (RIL has traditionally been growth focused and has generated superior return ratios) Potential investment in a new refinery at Jamnagar, most likely under RPL could be a large value creator for RIL on account of the favourable tax benefits under the first RPL refinery. Investment opportunities in E&P, SEZ, City gas projects along with overseas inorganic growth opportunities exist. New investment avenues like semiconductor are opening up and appear highly attractive, especially with the Government providing favourable terms. 5. Robust earnings growth – E&P and RPL key contributors